1. Articles in category: Cells and Stem Cells

    1-24 of 221 1 2 3 4 5 6 7 8 9 10 »
    1. The Transcription Regulator Krüppel-Like Factor 4 and Its Dual Roles of Oncogene in Glioblastoma and Tumor Suppressor in Neuroblastoma.

      The Transcription Regulator Krüppel-Like Factor 4 and Its Dual Roles of Oncogene in Glioblastoma and Tumor Suppressor in Neuroblastoma.

      For Immunopathol Dis Therap. 2016;7(1-2):127-139

      Authors: Ray SK

      Abstract The Krüppel-like factor 4 (KLF4) gene is located on chromosome 9q31.

      Read Full Article
    2. Anti-cancer stemness and anti-invasive activity of bitter taste receptors, TAS2R8 and TAS2R10, in human neuroblastoma cells.

      Anti-cancer stemness and anti-invasive activity of bitter taste receptors, TAS2R8 and TAS2R10, in human neuroblastoma cells.

      PLoS One. 2017;12(5):e0176851

      Authors: Seo Y, Kim YS, Lee KE, Park TH, Kim Y

      Abstract Neuroblastoma (NB) originates from immature neuronal cells and currently has a poor clinical outcome. NB cells possess cancer stem cells (CSCs) characteristics that facilitate the initiation of a tumor, as well as its metastasis.

      Read Full Article
      Mentions: Metastasis
    3. High-Risk Neuroblastoma with Metastases to Bilateral Kidneys at Diagnosis.

      High-Risk Neuroblastoma with Metastases to Bilateral Kidneys at Diagnosis.

      Case Rep Pediatr. 2017;2017:5375091

      Authors: Yoshikawa T, Tanizawa A, Suzuki K, Ikeda K, Nomura E, Maeda Y, Tanaka N, Yamada K, Sakai Y, Imamura Y, Ohshima Y

      Abstract Renal metastasis at diagnosis with neuroblastoma is rare. We present a 14-month-old boy who was diagnosed with high-risk neuroblastoma with multiple metastases, including bilateral kidneys.

      Read Full Article
      Mentions: Metastasis
    4. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

      Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

      Cochrane Database Syst Rev. 2017 Apr 21;4:CD010349

      Authors: Kraal KC, van Dalen EC, Tytgat GA, Van Eck-Smit BL

      Abstract BACKGROUND: Patients with newly diagnosed high-risk (HR) neuroblastoma (NBL) still have a poor outcome, despite multi-modality intensive therapy.

      Read Full Article
      Mentions: MIBG
    5. Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

      Conditions :   Childhood Ganglioneuroblastoma;   Childhood Neuroblastoma;   NMYC Gene Amplification;   Recurrent Neuroblastoma Interventions :   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate Sponsors :   Children's Oncology Group;   National Cancer Institute (NCI) Not yet recruiting - verified April 2017

      Read Full Article
    6. Management of Neuroblastoma: ICMR Consensus Document.

      Management of Neuroblastoma: ICMR Consensus Document.

      Indian J Pediatr. 2017 Apr 03;:

      Authors: Bansal D, Totadri S, Chinnaswamy G, Agarwala S, Vora T, Arora B, Prasad M, Kapoor G, Radhakrishnan V, Laskar S, Kaur T, Rath GK, Bakhshi S

      Abstract Neuroblastoma (NBL) is the most common extra-cranial solid tumor in childhood. High-risk NBL is considered challenging and has one of the least favourable outcomes amongst pediatric cancers.

      Read Full Article
      Mentions: Staging Relapse MYCN
    7. Physical and social characteristics and support needs of adult female childhood cancer survivors who underwent hormone replacement therapy.

      Physical and social characteristics and support needs of adult female childhood cancer survivors who underwent hormone replacement therapy.

      Int J Clin Oncol. 2017 Mar 31;:

      Authors: Tomioka A, Maru M, Kashimada K, Sakakibara H

      Abstract BACKGROUND: Female childhood cancer survivors who develop gonadal dysfunction require female hormone replacement therapy (HRT) from puberty until menopause. However, the support provided in such cases has not been studied.

      Read Full Article
    8. Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma.

      Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma.

      Mol Ther Oncolytics. 2017 Mar 17;4:67-76

      Authors: Gutova M, Goldstein L, Metz M, Hovsepyan A, Tsurkan LG, Tirughana R, Tsaturyan L, Annala AJ, Synold TW, Wan Z, Seeger R, Anderson C, Moats RA, Potter PM, Aboody KS

      Read Full Article
    9. HLA-E inhibitor enhances the killing of neuroblastoma stem cells by co-cultured dendritic cells and cytokine-induced killer cells loaded with membrane-based microparticles.

      HLA-E inhibitor enhances the killing of neuroblastoma stem cells by co-cultured dendritic cells and cytokine-induced killer cells loaded with membrane-based microparticles.

      Am J Cancer Res. 2017;7(2):334-345

      Authors: Zhen Z, Yang K, Ye L, You Z, Chen R, Liu Y, He Y

      Read Full Article
    10. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.

      Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.

      Eur J Cancer. 2017 Mar 19;76:188-196

      Authors: Kraal KC, Bleeker GM, van Eck-Smit BL, van Eijkelenburg NK, Berthold F, van Noesel MM, Caron HN, Tytgat GA

      Read Full Article
      Mentions: GPOH MIBG
    11. A c-Myc-regulated stem cell-like signature in high-risk neuroblastoma: A systematic discovery (Target neuroblastoma ESC-like signature).

      A c-Myc-regulated stem cell-like signature in high-risk neuroblastoma: A systematic discovery (Target neuroblastoma ESC-like signature).

      Sci Rep. 2017 Dec;7(1):41

      Authors: Yang XH, Tang F, Shin J, Cunningham JM

      Abstract c-Myc dysregulation is hypothesized to account for the 'stemness' - self-renewal and pluripotency - shared between embryonic stem cells (ESCs) and adult aggressive tumours.

      Read Full Article
    12. Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma.

      Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma.

      BMC Cancer. 2017 Feb 24;17(1):156

      Authors: Bayat Mokhtari R, Baluch N, Ka Hon Tsui M, Kumar S, S Homayouni T, Aitken K, Das B, Baruchel S, Yeger H

      Abstract BACKGROUND: Neuroblastoma (NB), a tumor of the primitive neural crest, despite aggressive treatment portends a poor long-term survival for patients with advanced high stage NB. New treatment strategies are required.

      Read Full Article
      Mentions: Treatment
    13. Didymin: an orally active citrus flavonoid for targeting neuroblastoma.

      Didymin: an orally active citrus flavonoid for targeting neuroblastoma.

      Oncotarget. 2017 Feb 08;:

      Authors: Singhal SS, Singhal S, Singhal P, Singhal J, Horne D, Awasthi S

      Abstract Neuroblastoma, a rapidly growing yet treatment responsive cancer, is the third most common cancer of children and the most common solid tumor in infants. Unfortunately, neuroblastoma that has lost p53 function often has a highly treatment-resistant phenotype leading to tragic outcomes.

      Read Full Article
      Mentions: Treatment MYCN
    14. Two investigational antitumor agents work better together against MPNST and neuroblastoma

      Two investigational antitumor agents work better together against MPNST and neuroblastoma

      Two investigational agents, Aurora A kinase inhibitor (alisertib) and HSV1716, a virus derived from HSV-1 and attenuated by the deletion of RL1, have shown some antitumor efficacy in early clinical trials as monotherapies. A new study published last week in Oncotarget, however, demonstrates that the combined usage of the agents results in significantly increased antitumor efficacy in models of malignant peripheral nerve sheath tumor (MPNST) and neuroblastoma.

      Read Full Article
    15. Clinical characteristics of infant neuroblastoma and a summary of treatment outcome.

      Clinical characteristics of infant neuroblastoma and a summary of treatment outcome.

      Oncol Lett. 2016 Dec;12(6):5356-5362

      Authors: Zhang Y, Huang D, Zhang W, Tang S, Han T, Zhu X, Liu A, Zhi T

      Abstract Neuroblastoma (NB) is the most common malignant solid tumor in the peripheral nervous system in infants and young children, with a high degree of malignancy. The clinical characteristics and prognosis of NB in infants are unique.

      Read Full Article
      Mentions: Treatment NSE
    16. Skeletal outcome in long-term survivors of childhood high-risk neuroblastoma treated with high-dose therapy and autologous stem cell rescue.

      Skeletal outcome in long-term survivors of childhood high-risk neuroblastoma treated with high-dose therapy and autologous stem cell rescue.

      Bone Marrow Transplant. 2017 Jan 09;:

      Authors: Utriainen P, Vatanen A, Toiviainen-Salo S, Saarinen-Pihkala U, Mäkitie O, Jahnukainen K

      Read Full Article
      Mentions: Bone Marrow
    17. Incorporation of high-dose (131) I-metaiodobenzylguanidine treatment into killer immunoglobulin-like receptor/HLA-ligand mismatched haploidentical stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplanta

      Incorporation of high-dose (131) I-metaiodobenzylguanidine treatment into killer immunoglobulin-like receptor/HLA-ligand mismatched haploidentical stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplantation.

      Pediatr Blood Cancer. 2016 Dec 24;:

      Authors: Lee JW, Kang ES, Sung KW, Yi E, Lee SH, Yoo KH, Koo HH

      Read Full Article
      Mentions: Treatment MIBG GvHD
    18. Resistance of stem-like cells from neuroblastoma cell lines to commonly used anticancer drugs.

      "Neuroblastoma lines SK-N-BE and SK-N-SH had 2% and 8% cells expressing CD133 respectively, while SH-SY-5Y had no CD133 expressing cells. CD133 + cells showed significant resistance to all four drugs in the MTT assay as well as the PI/Annexin binding assay compared to CD 133 - cells. This study suggests that CD133+ cells in neuroblastoma cell lines are more resistant to conventional anti-cancer drugs compared to CD133- cells. Targeting these stem-like cell populations could lead to development of more effective treatment for neuroblastoma."

      Read Full Article
      Mentions: Relapse
    19. CD114: A New Member of the Neural Crest-Derived Cancer Stem Cell Marker Family.

      "Patients with neural crest-derived tumors often have poor outcomes due to frequent relapses, likely due to the continued presence of residual treatment-resistant CSCs, and therapies directed against these CSCs are likely to improve patient outcomes. CSCs share many of the same genetic and biologic features of primordial neural crest cells, and therefore a better understanding of neural crest development will likely lead to the development of effective therapies directed against these CSCs. Signaling through STAT3 has been shown to be required for neural crest development, and granulocyte colony stimulating factor (GCSF)-mediated activation of STAT3 has been shown to play ...

      Read Full Article
    20. Loss of a microRNA family, let-7, found key in neuroblastoma

      Loss of a microRNA family, let-7, found key in neuroblastoma

      "The let-7 family of microRNAs (bits of genetic code that regulate genes) is known to be involved in both stem-cell differentiation and tumor suppression. Recent research had implicated LIN28B, a protein that inhibits let-7 maturation, in neuroblastoma. But the new study, through work on neuroblastoma cells and analysis of patient data, found that LIN28B is only one of several cancer mechanisms that involve let-7 suppression.  "We're showing that let-7 inhibition is central to the development of this disease," Powers says. "So critical in fact that neuroblastoma uses at least three distinct ways of eliminating it."  Powers and colleagues first ...

      Read Full Article
      Mentions: MYCN Chemotherapy
    21. Induced differentiation inhibits sphere formation in neuroblastoma.

      "Here, we show that MYCN-amplified neuroblastoma cell lines form spheres more frequently than non-MYCN-amplified cell lines. We also show that sphere formation is directly sensitive to cellular differentiation status. 13-cis-retinoic acid is a clinically used differentiating agent that induces a neuronal phenotype in neuroblastoma cells. Induced differentiation nearly completely blocked sphere formation. Furthermore, sphere formation was specifically FGF-responsive and did not respond to increasing doses of EGF. Taken together, these data suggest that sphere formation is an accurate method of quantifying the stemness phenotype in neuroblastoma."

      Read Full Article
      Mentions: Treatment MYCN
    1-24 of 221 1 2 3 4 5 6 7 8 9 10 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (2 articles) Metastasis